BioLineRx Ltd. and Compugen Ltd. Company Profile
BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRxâs current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction has completed a Phase I/II study and has been out-licensed to Ikaria Inc. for a total deal value of $282.5 million, in addition to sales royalties; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development and BL-7040 for treating Inflammatory Bowel Disease (IBD) has completed Phase I. In addition, BioLineRx has nine products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.
News Articles
Compugen subsidiary secures up to $15M
Compugen Ltd. (NASDAQ:CGEN) said its Keddem Bioscience Ltd. subsidiary secured up to $15 million from an undisclosed U.S. investor to develop and commercialize the subsidiary's discovery technology fo...
Compugen, Merck Serono form Israeli biomarker JV
Compugen Ltd. (NASDAQ:CGEN) and Merck Serono S.A. launched Neviah Genomics Ltd., an Israeli JV focused on developing biomarker tests to predict drug-induced toxicity. Merck Serono Ventures will provid...
Compugen's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Compugen Ltd. (CGEN) Q1 2013 Earnings Call April 25, 2013 10:00 am ET Executives Martin Gerstel – Chairman Dikla Czaczkes Axselbrad – Chief Financial Officer Anat Cohen-Dayag – President...
Merck Serono, Compugen to set-up new biomarker company
Merck Serono, a division of Merck, Darmstadt, Germany, and Compugen have announced the establishment of a new biomarker company, Neviah Genomics.
BioLineRx: 'Bench to Bedside to Partner' - Bridging the gap between academia and pharma
In this episode of PharmaTelevision News Review, filmed in Amsterdam at BioEurope Spring 2012, Fintan Walton talks to David Malek, Vice Preident of Business Development of BioLineRx.
BioLineRx Rises On New Schizophrenia Drug Data
NEW YORK (AP) — Shares of BioLineRx jumped nearly 11 percent Tuesday after the company released results from a new clinical trial of its schizophrenia drug.
Compugen to Present at the 12th Annual Needham Healthcare Conference
Compugen Ltd. (NASDAQ: CGEN) today announced that its President and Chief Executive Officer, Dr. Anat Cohen-Dayag, will be presenting at the 12th Annual Needham Healthcare...
[Compugen] and [Merck Serono] launch [Neviah Genomics], for predictive biomarker discovery
[Compugen Ltd.] (protein and monoclonal antibody drug discovery for cancer and immune-mediated diseases) has joined up with partner [Merck Serono SA] to form [Neviah Genomics Ltd.], an Israeli firm th...
Drugs and Medications
None
PubMed Articles
Improving classical substructure-based virtual screening to handle extrapolation challenges.
Target-oriented substructure-based virtual screening (sSBVS) of molecules is a promising approach in drug discovery. Yet, there are doubts whether sSBVS is suitable also for extrapolation, that is, fo...
Clinical Trials
None
Companies
BioLineRx Ltd. and Compugen Ltd.
BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over curr...
BioLineRx's ultimate mission is to improve the health of people throughout the world with compounds that make for better and longer lives. Founded in 2003 by leaders in the Israeli life-sciences secto...
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are b...
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based...
Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology...
More Information about "BioLineRx Ltd. and Compugen Ltd." on BioPortfolio
We have published hundreds of BioLineRx Ltd. and Compugen Ltd. news stories on BioPortfolio along with dozens of BioLineRx Ltd. and Compugen Ltd. Clinical Trials and PubMed Articles about BioLineRx Ltd. and Compugen Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioLineRx Ltd. and Compugen Ltd. Companies in our database. You can also find out about relevant BioLineRx Ltd. and Compugen Ltd. Drugs and Medications on this site too.
